Clinical trial NCT02754167: Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
Official title: Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Anemia of Chronic Kidney Disease
Keywords: Hepcidin
hemoglobin
iron
anemia of chronic disease
Lead sponsor: Pieris Pharmaceuticals GmbH
Sponsor class: INDUSTRY
Collaborators: name: FGK Clinical Research GmbH
First posted: 2016-04-28
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Anticalins® are engineered human proteins that are able to bind specific target molecules. The Anticalin PRS-080#022-DP to be investigated in this study is directed against hepcidin and is intended for the treatment of anemia of chronic disease. This Phase Ib study shall investigate the safety, pharmacokinetics and pharmacodynamics of a single administration of PRS-080#022-DP in anemic stage 5 chronic kidney disease patients undergoing hemodialysis.

Detailed description: This is a multi-center, randomized, double-blind, placebo-controlled, single ascending dose phase Ib study in anemic stage 5 chronic kidney disease patients requiring hemodialysis. Eligible subjects will undergo screening assessments and PRS-080#22-DP will be administered by intravenous infusion. The study will consist of 3 dose cohorts of 2 mg/kg, 4 mg/kg, and 8 mg/kg body weight with 8 subjects in each cohort. Using a standard 6+2 design, 6 subjects in each cohort will be randomized to PRS-080#022-DP and 2 subjects in each cohort will be randomized to placebo. The decision to escalate the dose will be based on an interim analysis of clinical safety and safety laboratory data. Safety and tolerability, pharmacokinetics, pharmacodynamics as well as potential immunogenicity will be investigated.

Eligibility criteria: Inclusion Criteria:

* Patients with stage 5 chronic kidney disease having been on hemodialysis for at least 90 days
* Patients being on stable erythropoiesis-stimulating agent (ESA) dose
* Hemoglobin (Hb) 9 - 11 g/dL
* Ferritin ≥ 300 ng/mL.
* Transferrin saturation (TSAT) ≤ 30%
* Hepcidin 5 - 50 nmol/L

Exclusion Criteria:

* Anemia due to causes other than chronic kidney disease, including hemoglobinopathies, hemolytic anemias, myelodysplasia or malignancy
* Blood transfusion within 2 months before administration of study medication.
* Iron treatment from 1 week before study medication administration until 1 week after study medication administration.
* Previous enrollment in this study
* Current or previous (within 60 days before study medication administration) treatment with another investigational drug and/or medical device or participation in another clinical study.
* Pregnancy or breast-feeding women of child bearing age.
* Known allergy to any component of the PRS-080#022-DP formulation
* Positive for hepatitis B surface antigen, anti-hepatitis C virus antibody, or human immunodeficiency virus
* Planned surgery during the study period
* Unwilling or unable to comply with the protocol, in the judgment of the investigator
* Unstable angina, myocardial infarction, percutaneous transluminal coronary angioplasty/stents, apoplexy or coronary artery bypass grafting \<3 months prior screening.
* Congestive heart failure: New York Heart Association Class III or IV.

Primary outcomes:
measure: Number of patients with adverse events
timeFrame: 28 days
Secondary outcomes:
measure: Pharmacokinetics of PRS-080#022
timeFrame: 28 days
measure: Effects of PRS-080#022 on serum iron
timeFrame: 28 days
measure: Effects of PRS-080#022 on ferritin
timeFrame: 28 days
measure: Effects of PRS-080#022 on transferrin saturation
timeFrame: 28 days
measure: Effect of PRS-080#022 on hepcidin concentrations in plasma
timeFrame: 28 days
measure: Number of patients developing anti-drug antibodies
timeFrame: 28 days
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: St. Joseph Krankenhaus
city: Munich
country: Germany
facility: Technical University, Medical Department
Study officials:
affiliation: Technical University, Munich
name: Lutz Renders, Prof. MD
role: PRINCIPAL_INVESTIGATOR
References: